Three component chimeric antisense oligonucleotides

• US 5,849,902 A
• Filed: 11/21/1996
• Issued: 12/15/1998
• Est. Priority Date: 09/26/1996
• Status: Expired due to Term

• Current Assignee: Ribozyme Pharmaceuticals, Inc. (Alnylam Pharmaceuticals Incorporated), Lakewood Amedex Inc., Ologos ETC. Inc., Sequitur Inc. (Thermo Fisher Scientific Incorporated)
• Original Assignee: Oligos Etc., Inc., Tod Mitchell Woolf
• Inventors: Dale, Roderic M.K., Woolf, Tod Mitchell, Arrow, Amy
• Primary Examiner(s): LeGuyader, John L.
• Application Number:
  US08/754,580
• Time in Patent Office: 754 Days
• Field of Search: 435/91.1, 536/375, 536/23.1, 536/24.5, 536/24.3, 514/44
• US Class Current: 536/24.5
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/311 Phosphotriesters
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/317 with an inverted bond, e.g. a cap structure
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/346 having a combination of backbone and sugar modifications
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: C12N 2310/3523 Allyl
• CPC Class Codes: C12N 2310/3527 Other alkyl chain

Abstract

This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: a RNase H activating region, a complementarity region and 3'"'"' and 5'"'"' ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.

Claims

1. A chimeric antisense oligonucleotide comprising:

a 5'"'"' terminus;

a 3'"'"' terminus; and

from 11 to 59 5'"'"'→

3'"'"'-linked nucleotides independently selected from the group consisting of 2'"'"'-modified phosphodiester nucleotides, and 2'"'"'-modified P-alkyloxyphosphotriester nucleotides; and

wherein said 5'"'"' terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein

the 3'"'"' terminus of said oligonucleotide is drawn from the group consisting of;

an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'"'"'-modified ribonucleotides, a biotin group, and a P-alkyloxyphosphotriester nucleotide.

2. The oligonucleotide of claim 1, provided the 3'"'"' terminus is not blocked by a 3'"'"'→

3'"'"' phosphorothioate linked nucleotide.

3. The oligonucleotide of claim 1, in which the 3'"'"' terminus is blocked by a moiety comprising a 3'"'"'→

3'"'"' phosphorothioate linked nucleotide.

4. The oligonucleotide of claim 1, in which the 3'"'"' terminus is blocked by a moiety comprising a 3'"'"'→

3'"'"' phosphodiester linked nucleotide.

5. The oligonucleotide of claim 4, in which the 3'"'"' most 5'"'"'→

3'"'"' internucleotide linkage is a phosphorothioate linkage or a P-ethoxyphosphotriester linkage.

6. The oligonucleotide of claim 4, in which the 5'"'"' most 5'"'"'→

3'"'"' internucleotide linkage is a phosphorothioate linkage or a P-ethoxyphosphotriester linkage.

7. The oligonucleotide of claim 1, in which the 3'"'"' terminal nucleoside and the 5'"'"' most nucleotide are 2'"'"'-modified nucleotides.

8. The oligonucleotide of claim 1, in which the RNase H activating region comprises the 5'"'"' most nucleotide.

9. The oligonucleotide of claim 8, in which the 3'"'"' most 5'"'"'→

3'"'"' internucleotide linkage is a phosphorothioate linkage or a P-ethoxyphosphotriester linkage.

10. The oligonucleotide of claim 9, in which the two 3'"'"' most 5'"'"'→

3'"'"' internucleotide linkages are independently either a phosphorothioate linkage or a P-ethoxyphosphotriester linkage.

11. The oligonucleotide of claim 9, in which all phosphorothioate linkages are contiguous with the 5'"'"' most 5'"'"'→

3'"'"' internucleotide linkage.

12. The oligonucleotide of claim 11, in which the 2'"'"'-modified nucleotide is a 2'"'"'-methoxy or 2'"'"'-fluoro nucleotide.

13. The oligonucleotide of claim 11, which comprises at least thirteen 2'"'"'-methoxy phosphodiester nucleotides.

14. The oligonucleotide of claim 11, having between 15 and 50 nucleotides.

15. The oligonucleotide of claim 14, which comprises at least eight 2'"'"'-methoxy phosphodiester nucleotides.

16. The oligonucleotide of claim 14, which comprises at least thirteen 2'"'"'-methoxy phosphodiester nucleotides.

18. The oligonucleotide of claim 1, in which the 2'"'"'-modified nucleotides are selected from the group consisting of 2'"'"'-fluoro and 2'"'"'-methoxy nucleotides.

19. The oligonucleotide of claim 1, in which there are no 2'"'"'-modified phosphorothioate nucleotides.

17. A chimeric antisense oligonucleotide, comprising:

a 5'"'"' terminus;

a 3'"'"' terminus; and

from 11 to 59 5'"'"'→

3'"'"'-linked nucleotides independently selected from the group consisting of 2'"'"'-modified phosphodiester nucleotides, and 2'"'"'-modified P-alkyloxyphosphotriester nucleotides; and

wherein said 3'"'"' terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 5'"'"' terminus of said oligonucleotide is drawn from the group consisting of;

an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'"'"'-modified ribonucleotides, a biotin group, and a P-alkyloxyphosphodiester nucleotide.

20. A method of specifically cleaving an RNA in a cell containing RNase H which comprises administering an effective amount of an oligonucleotide complementary to the RNA comprising:

a 5'"'"' terminus;

a 3'"'"' terminus; and

from 11 to 59 5'"'"'→

3'"'"'-linked nucleotides independently selected from the group consisting of 2'"'"'-modified phosphodiester nucleotides, 2'"'"'-modified P-alkyloxyphosphotriester nucleotides; and

wherein said 5'"'"' terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein

the 3'"'"' terminus of said oligonucleotide is drawn from the group consisting of;

an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate deoxyribonucleotides, phosphorothioate 2'"'"'-modified ribonucleotides, a biotin group, and a P-alkyloxyphosphodiester-linked nucleotide.

21. A chimeric antisense oligonucleotide comprising:

a) a 5'"'"' terminal RNase H activation region having between 5 and 10 contiguous deoxyphosphorothioate nucleotides;

b) between 11 to 59 contiguous 5'"'"'→

3'"'"'-linked 2'"'"'-methoxy ribonucleotides; and

c) an exonuclease blocking group present at the 3'"'"' end of the oligonucleotide that is drawn from the group consisting of;

a non-5'"'"'-3'"'"' phosphodiester-linked nucleotide, from one to three contiguous 5'"'"'-3'"'"'-linked modified nucleotides, and a non-nucleotide chemical blocking group.

22. The oligonucleotide of claim 21, wherein said non-5'"'"'-3'"'"' phosphodiester-linked nucleotide is drawn from the group consisting of:

a 3'"'"'--3'"'"'-linked nucleotide, a phosphorothioate 2'"'"'-modified ribonucleotide, and a P-alkyloxyphosphodiester-linked nucleotide.

23. The oligonucleotide of claim 21, wherein said chemical non-nucleotide chemical blocking group is biotin.